Addressing artifacts of colorimetric anticancer assays for plant-based drug development
- PMID: 36071299
- DOI: 10.1007/s12032-022-01791-z
Addressing artifacts of colorimetric anticancer assays for plant-based drug development
Abstract
Cancer has become the silent killer in less-developed countries and the most significant cause of morbidity worldwide. The accessible and frequently used treatments include surgery, radiotherapy, chemotherapy, and immunotherapy. Chemotherapeutic drugs traditionally involve using plant-based medications either in the form of isolated compounds or as scaffolds for synthetic drugs. To launch a drug in the market, it has to pass through several intricate steps. The multidrug resistance in cancers calls for novel drug discovery and development. Every year anticancer potential of several plant-based compounds and extracts is reported but only a few advances to clinical trials. The false-positive or negative results impact the progress of the cell-based anticancer assays. There are several cell-based assays but the widely used include MTT, MTS, and XTT. In this article, we have discussed various pitfalls and workable solutions.
Keywords: Anticancer; Anticancer drugs; Colorimetric assays; Drug development; MTS; MTT; Pitfalls or solutions; XTT.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Comparative analysis of using MTT and XTT in colorimetric assays for quantitating bovine neutrophil bactericidal activity.J Immunol Methods. 1993 Jan 4;157(1-2):225-31. doi: 10.1016/0022-1759(93)90091-k. J Immunol Methods. 1993. PMID: 8423367
-
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Epub 2015 Mar 23. Eur J Pharm Biopharm. 2015. PMID: 25813885 Review.
-
Anticancer Drug Development: The Way Forward.Oncologist. 1996;1(3):180-181. Oncologist. 1996. PMID: 10387985
-
Interference by anti-cancer chemotherapeutic agents in the MTT-tumor chemosensitivity assay.Chemotherapy. 2004 Apr;50(1):43-50. doi: 10.1159/000077285. Chemotherapy. 2004. PMID: 15084806
-
Heterocyclic Scaffolds: Centrality in Anticancer Drug Development.Curr Drug Targets. 2015;16(7):711-34. doi: 10.2174/1389450116666150309115922. Curr Drug Targets. 2015. PMID: 25751009 Review.
Cited by
-
Green synthesis of silver nanoparticle prepared with Ocimum species and assessment of anticancer potential.Sci Rep. 2024 May 22;14(1):11707. doi: 10.1038/s41598-024-61946-y. Sci Rep. 2024. PMID: 38777818 Free PMC article.
-
Morphological Characterization, Polyphenolic Profile, and Bioactive Properties of Limoncella, an Ancient Mediterranean Variety of Sweet Citrus.Biomolecules. 2024 Oct 10;14(10):1275. doi: 10.3390/biom14101275. Biomolecules. 2024. PMID: 39456208 Free PMC article.
References
-
- Ediriweera MK, Tennekoon KH, Samarakoon SR. In vitro assays and techniques utilized in anticancer drug discovery. Appl Toxicol. 2019;39(1):38–71. - DOI
-
- Rayan A, Raiyn J, Falah M. Nature is the best source of anticancer drugs: indexing natural products for their anticancer bioactivity. J PLoS one. 2017;12(11):187925. - DOI
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2021;71(3):209–49. - PubMed
-
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. J CA. 2015;65(2):87–108. - PubMed
-
- Dube PN, Sakle NS, Dhawale SA, More SA, Mokale SN. Synthesis, biological investigation and docking study of novel chromen derivatives as anti-cancer agents. Anti-Cancer Agents Med Chem. 2019;19(9):1150–60. - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources